Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer
Wang L, Zhai YQ, Xu LL, Qiao C, Sun XL, Ding JH, et al
While theoretically concerning, existing data suggest that combination agents using glucagon agonism do not produce greater-than-expected contractile muscle loss
J Clin Endocrinol Metab (2005) 90(12):660915
Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data
73 LuX.WangZ
